



IPOS copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶: C07D 498/22, A61K 47/16	A1	(11) International Publication Number: WO 97/41127 (43) International Publication Date: 6 November 1997 (06.11.97)
(21) International Application Number: PCT/US97/07302 (22) International Filing Date: 30 April 1997 (30.04.97) (30) Priority Data: 60/016,382 1 May 1996 (01.05.96) US (71) Applicants (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). MISSISSIPPI STATE UNIVERSITY [US/US]; 305 Bowen Hall, Mississippi State, MS 39762 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): JIROUSEK, Michael, R. [US/DE]; Heimhuder Strasse #76, D-20148 Hamburg (DE). GOEKJIAN, Peter, G. [US/US]; 518 Greensboro Street, Starkville, MS 39759 (US). WU, Guo-Zhang [CN/US]; 27 M. Mississippi Village, Starkville, MS 39759 (US). (74) Agent: LAMMERT, Steven, R.; Barnes & Thornburg, 1313 Merchants Bank Building, 11 South Meridian Street, Indianapolis, IN 46204 (US).		(81) Designated States: AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, FI, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RU, SD, SG, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. 1st W. add. changed already. See PF 23 2/13/99.
(54) Title: HALO-SUBSTITUTED PROTEIN KINASE C INHIBITORS (57) Abstract The present invention is directed to novel halo-substituted bis-indolemaleimide compounds of formula (I). The invention further provides a method of preparing the disclosed compounds and the preparation of pharmaceutical formulation for use in inhibiting Protein Kinase C in mammals. (I)		